Subject demographics and clinical characteristics at enrolment (day −21)
| Placebo (n=14) | Timapiprant (n=16) | |
| Age (years) | 25.4 (3.8) | 25.3 (8.9) |
| Sex | ||
| Male | 5 (36%) | 7 (44%) |
| Female | 9 (64%) | 9 (56%) |
| Body mass index (kg/m2) | 23.8 (2.4) | 24.8 (4.3) |
| Inhaled corticosteroid dose (beclometasone dipropionate equivalent μg/day) | 366 (356) | 519 (281) |
| Long acting β2 agonist use (no.) | 6 (43%) | 8 (53%) |
| ACQ-6 | 1.20 (0.72) | 1.32 (0.79) |
| FEV1 (litres) | 3.57 (3.32–4.03) | 3.55 (2.98–4.32) |
| FEV1 (% predicted) | 93 (80–98) | 94 (78–102) |
| PC20 (mg/mL histamine) | 1.30 (0.63–4.73) | 1.79 (0.53–3.93) |
| FeNO (parts per billion) | 30.5 (21.8–67.3) | 38.0 (25.3–69.3) |
| Blood eosinophils (cells × 109/L) | 0.30 (0.20–0.40) | 0.35 (0.23–0.48) |
| Total serum IgE (IU/mL) | 190 (117–289) | 398 (106–692) |
| Skin prick test responses (total positive) | 3.7 (1.5) | 4.5 (1.5) |
| Ex-smoker (no.) | 1 (7.1%) | 2 (12.5%) |
| Smoking pack years | 0.04 (0.13) | 0.53 (2.00) |
| Ex-smokers only | 0.50 (not applicable) | 4.25 (5.30) |
Data are number (%), mean (SD), or median (IQR).
ACQ, Asthma Control Questionnaire; FeNO, fractional exhaled nitric oxide ; FEV1, forced expiratory volume in 1 second; IgE, immunoglobulin E; PC20, provocation concentration of histamine required to produce a 20% drop in FEV1.